

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

Comparative study on the efficacy of add-on sertraline or dapoxetine to PDE-5 inhibitors (phosphodiesterase type 5) on the erectile function and intra-vaginal ejaculation latency time (IELT) among patients with concomitant erectile dysfunction and premature ejaculation

Protocol summary

Erectile function, Premature ejaculation

Study aim

Determining the effectiveness of adding sertraline and dapoxetine (phosphodiesterase inhibitors type 5) on erectile function and latent and intravaginal ejaculation time in patients with concomitant erectile dysfunction and premature ejaculation

Design

Clinical trial with control group, with parallel groups, one-way blind, randomized, phase-3 on 50 patients. SPSS software was used for randomization.

Settings and conduct

This double-blind clinical trial study was performed in 1400 in psychiatric therapists of Khorshid Hospital in Isfahan. In this study, the patient and the person examining the outcome of the treatment will be unaware of the type of medication received by patients.

Participants/Inclusion and exclusion criteria

In this study, patients with erectile dysfunction and premature ejaculation are included in the study. Patients with genitourinary tract infection, neurological disorders and underlying diseases, and people with Selective Serotonin Reuptake Inhibitors (SSRI) allergies or a history of pelvic surgery will not be included in the study.

Intervention groups

50 patients with sexual dysfunction are distributed in two groups of 25 people. The first group will receive 60 mg of dapoxetine one to three hours before sexual activity, and the second group will receive 50 mg of sertraline twice daily for one month. This will continue for 3 months. Then, the duration of intravaginal ejaculation in all individuals (average time in at least three sexual intercourses), at the beginning of the study and also in weeks 4, 8 and 12 after starting the drug by the spouse from the time of vaginal penetration to the time of ejaculation with a stopwatch will be measured.

Main outcome variables

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20150913024006N5**

Registration date: **2021-03-02, 1399/12/12**

Registration timing: **prospective**

Last update: **2021-03-02, 1399/12/12**

Update count: **0**

Registration date

2021-03-02, 1399/12/12

Registrant information

Name

Mitra Molaeinezhad

Name of organization / entity

Isfahan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 31 3222 2135

Email address

m_molaei@bsrc.mui.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-04-03, 1400/01/14

Expected recruitment end date

2022-03-18, 1400/12/27

Actual recruitment start date

empty
Actual recruitment end date
empty
Trial completion date
empty

Scientific title
Comparative study on the efficacy of add-on sertraline or dapoxetine to PDE-5 inhibitors (phosphodiesterase type 5) on the erectile function and intra-vaginal ejaculation latency time (IELT) among patients with concomitant erectile dysfunction and premature ejaculation

Public title
The effect of adding sertraline to dapoxetine in relieving sexual problems in men

Purpose
Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Erectile dysfunction and a score above 20 in the International Index of Erectile Function Treatment with phosphodiesterase 5 inhibitors (such as Sildenafil, Tadalafil) more than three months before the start of the study Living in a stable and heterosexual relationship and intention for maintaining the relationship until the end of the study period Possibility of sexual intercourse at least once a week

Exclusion criteria:

Sensitivity to Selective Serotonin Reuptake Inhibitors (SSRI) drugs Urinary tract infections Neurological disorders History of pelvic surgery Underlying diseases such as diabetes, heart disease, hypertension, thyroid disorder Use of psychiatric drugs Alcohol consumption

Age
From **18 months** old to **80 months** old

Gender
Male

Phase
3

Groups that have been masked

- Participant
- Outcome assessor

Sample size
Target sample size: **50**

Randomization (investigator's opinion)
Randomized

Randomization description
For randomization patients in the two groups simple randomization is used. For this purpose, 50 pieces of paper with the letter A written on 25 of them and the letter B written on the other 25 pieces are poured into the box. Each patient is asked to take a sheet out of the box when entering the study. Depending on what is written on the sheet, the patient enters the first group (A) or the second group (B).

Blinding (investigator's opinion)
Double blinded

Blinding description
This study is performed by two-blind method.

Medications in similar packages prepared by the pharmaceutical company are provided by the researcher to patients who are unaware of the contents of the packages. The outcome of treatment is also assessed by another psychiatrist who is unaware of the type of medication the patient is receiving.

Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids
empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Isfahan University of Medical Sciences

Street address

Research faculty, Isfahan University of Medical Sciences, Hezarjerib street

City

Isfahan

Province

Isfahan

Postal code

8434193474

Approval date

2020-05-19, 1399/02/30

Ethics committee reference number

IR.MUI.MED.REC.1399.766

Health conditions studied

1

Description of health condition studied

Erectile dysfunction

ICD-10 code

N52

ICD-10 code description

Male erectile dysfunction

Primary outcomes

1

Description

Erectile function

Timepoint

Before the intervention and 4, 8, 12 weeks after the start of the intervention

Method of measurement

Erectile Performance Index Questionnaire

2

Description

Premature ejaculation

Timepoint

Before the intervention and 4, 8, 12 weeks after the start of the intervention

Method of measurement

The interval between the beginning of sexual intercourse and the time of ejaculation in minutes in the before the intervention and 4, 8, 12 weeks after the start of the intervention

Secondary outcomes

1

Description

Premature ejaculation

Timepoint

Before the intervention and 4, 8, 12 weeks after the start of the intervention

Method of measurement

The interval between the beginning of sexual intercourse and the time of ejaculation in minutes

Intervention groups

1

Description

Intervention group 1: This group of patients take a 60 mg oral tablet of dapoxetine made by Exir Pharmaceutical Company one to three hours before the start of sexual activity with the maximum allowed dose for 24 hours.

Category

Treatment - Drugs

2

Description

Intervention group 2: This group takes a 50 mg Sertraline tablet made by Osweh Pharmaceutical Company twice a day for a month.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Psychiatry clinic, Noor hospital

Full name of responsible person

Niloufar Kiani

Street address

Psychatri clinic, Noor hospital, Ostandari street

City

Isfahan

Province

Isfahan

Postal code

8434193474

Phone

+98 31 3669 2174

Email

kiani1357@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Shaghayegh Haghjoo

Street address

Research faculty, Isfahan University of Medical Science, Hezarjerib street

City

Isfahan

Province

Isfahan

Postal code

8434193474

Phone

+98 31 3792 3060

Email

sh_haghjoo@med.mui.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Esfahan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Niloufar kiani

Position

Resident

Latest degree

Specialist

Other areas of specialty/work

Psychiatrics

Street address

Department of psychology, Noor hospital, Ostandari street

City

Isfahan

Province

Isfahan

Postal code

8434193474

Phone

+98 31 3669 2174

Email

kiani1357@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Mitra Molaeinejad

Position

Assistant professor

Latest degree

Specialist

Other areas of specialty/work

Psychiatrics

Street address

Department of psychology, Noor hospital, Ostandari street

City

Isfahan

Province

Isfahan

Postal code

8434193474

Phone

+98 31 3669 2174

Email

M_molaei@bsrc.mui.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Esfahan University of Medical Sciences

Full name of responsible person

Ali Mehrabi

Position

Statistical consultant

Latest degree

Master

Other areas of specialty/work

Epidemiology

Street address

Research faculty, school of medicine, Isfahan University of Medical Sciences, Hezarjerib street

City

Isfahan

Province

Isfahan

Postal code

8434193474

Phone

+98 31 3669 2174

Email

al.mehrabi@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

The plan belongs to a government agency and cannot be shared.

Study Protocol

No - There is not a plan to make this available

Statistical Analysis Plan

No - There is not a plan to make this available

Informed Consent Form

No - There is not a plan to make this available

Clinical Study Report

No - There is not a plan to make this available

Analytic Code

No - There is not a plan to make this available

Data Dictionary

No - There is not a plan to make this available